SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/A844CD47ECB22867204E134854746EF3D93AD586BF2EE39A82610477541C1581920AFA240AF1FB86F297260E4DFDACEB>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/A844CD47ECB22867204E134854746EF3D93AD586BF2EE39A82610477541C1581920AFA240AF1FB86F297260E4DFDACEB
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/A844CD47ECB22867204E134854746EF3D93AD586BF2EE39A82610477541C1581920AFA240AF1FB86F297260E4DFDACEB
http://www.w3.org/2000/01/rdf-schema#comment
"Data show that on the basis of the structural differences between CA IX and the other membrane-associated alpha-CAs the rational drug design of isozyme-specific CA inhibitors are proposed."
xsd:string
http://purl.uniprot.org/uniprot/#_FA259F278F7F522A9FE7E7E3CBF491DA8656AD6FD9C67F1F284D01C3248E6A0F29121BF7C854FEA1F18120CD8F494823
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/A844CD47ECB22867204E134854746EF3D93AD586BF2EE39A82610477541C1581920AFA240AF1FB86F297260E4DFDACEB
http://purl.uniprot.org/uniprot/A0A0S2Z3D0
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/A844CD47ECB22867204E134854746EF3D93AD586BF2EE39A82610477541C1581920AFA240AF1FB86F297260E4DFDACEB
http://purl.uniprot.org/uniprot/#_A0A0S2Z3D0-mappedCitation-19805286
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/A844CD47ECB22867204E134854746EF3D93AD586BF2EE39A82610477541C1581920AFA240AF1FB86F297260E4DFDACEB